FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down,
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
The FDA declared the shortage of Novo Nordisk's weight-loss drugs over, giving compounders until May to stop making ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback